



Press Release

Biocon appoints Anupam Jindal as its Chief Financial Officer

For immediate release

BENGALURU, India – September 22, 2020

Biocon Limited (BSE: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced today that Anupam Jindal has been appointed as the company's new Chief Financial Officer (CFO). Anupam will head the finance function at Biocon and be part of the Executive Leadership Team. He will report into the company's Chief Executive Officer & Managing Director, Siddharth Mittal.

Prior to joining Biocon, Anupam worked with the Vedanta Group of companies for 22 years, where he held the position of Group Chief Financial Officer at Sterlite Technologies Limited since 2006. Anupam played a key role in growing the company's revenue exponentially through organic capacity expansion and acquisitions, in India and abroad. He was also instrumental in driving several strategic initiatives, such as inception and growth of new business verticals.

Anupam holds a Bachelor of Commerce (B Com) degree from ML Sukhadia University, Udaipur. He is also a Chartered Accountant from the Institute of Chartered Accountants of India and a Company Secretary from the Institute of Company Secretaries of India.

Biocon's Chief Executive Officer and Managing Director, Siddharth Mittal said, "We are pleased to have Anupam join us at this crucial phase of our growth, as we expand our portfolio and enter new geographies, to address patient needs for affordable, high-quality medicines. With his proven track record of steering high-growth companies, Anupam will play a key role in helping deliver on our business goals."

About Biocon Limited

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

Media:

BIOCON LIMITED

Calvin Printer

+91 80 2808 2132

Email: calvin.printer@biocon.com

Investor Relations:

BIOCON LIMITED

Saurabh Paliwal

+91 80 6775 2040

Email: investor.relations@biocon.com